EXTON, Pa.--(BUSINESS WIRE)--May 30, 2006--Antares Pharma, Inc. (Amex:AIS - News) announced today that Eli Lilly and Company (Lilly) has filed a provisional patent application with Antares for a needle-free injection device that is the result of joint development work done under the September 2003 agreement with Lilly. This agreement provides for development of needle-free injection devices in the fields of diabetes and obesity. The filing incorporates development work focused on making products more patient friendly related to the Antares’ core needle-free injector technology. This work could enhance the needle-free technology that Antares already sells into the U.S. insulin market as the MediJector VISION®. The intellectual property sought is the result of user and engineering studies focused on helping diabetics with their daily insulin requirements and eliminating needles from their lives. In addition to needle-free injections’ obvious advantages, the completed work has made other aspects of the injection even more user friendly. The development work that has been completed, and for which broad patent protection is sought, is in the area of “ease of use”.
